Borderline personality disorder

Summary

Borderline personality disorder (MONDO:0001156) is a disease and 249 clinical trials. Top therapeutic interventions include citalopram, fluoxetine, and quetiapine. A subtype of personality disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 249

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	borderline personality disorder
Mondo ID	MONDO:0001156
MeSH	D001883
DOID	DOID:10930
ICD-10-CM	F60.3
ICD-11	189289487
NCIT	C92633
SNOMED CT	20010003
UMLS	C0006012
MedGen	14197
Is cancer (heuristic)	no

Also known as: borderline personality disorder · borderline personality disorder (disease) · BPD

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of personality disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › personality disorder › borderline personality disorder

Related subtypes (9): schizotypal personality disorder, dependent personality disorder, obsessive-compulsive personality disorder, schizoid personality disorder, paranoid personality disorder, antisocial personality disorder, avoidant personality disorder, narcissistic personality disorder, histrionic personality disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Naltrexone	Phase 3 (in late-stage trials)
Olanzapine	Phase 3 (in late-stage trials)
Quetiapine	Phase 3 (in late-stage trials)
Selegiline	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetaminophen, Amylase (Pancrelipase), Brexpiprazole, Escitalopram, Hydrocortisone, Incobotulinumtoxina, Ketamine, Midazolam, Mifepristone, Ziprasidone.

Clinical trials & evidence

Clinical trials

Clinical trials: 249.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	196
PHASE2	26
PHASE3	11
PHASE4	6
PHASE1	5
PHASE1/PHASE2	3
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00178061	PHASE4	COMPLETED	Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder
NCT00204347	PHASE4	COMPLETED	Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder
NCT00533117	PHASE4	COMPLETED	Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder
NCT00634062	PHASE4	COMPLETED	Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder
NCT00834834	PHASE4	COMPLETED	Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder
NCT06018727	PHASE4	WITHDRAWN	Role Of Sensitivity to neuroEndocrine Systems in Social Decisions
NCT00088036	PHASE3	COMPLETED	Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder
NCT00091650	PHASE3	COMPLETED	Olanzapine in Patients With Borderline Personality Disorder
NCT00122070	PHASE3	COMPLETED	Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
NCT00124839	PHASE3	TERMINATED	Naltrexone in Borderline Personality Disorder
NCT00463775	PHASE3	WITHDRAWN	Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence
NCT00538135	PHASE3	COMPLETED	BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder
NCT00880919	PHASE3	COMPLETED	Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)
NCT01912391	PHASE3	COMPLETED	Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder
NCT03677037	PHASE3	COMPLETED	The Short-Term MBT Project
NCT04186403	PHASE2/PHASE3	COMPLETED	Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
NCT04440670	PHASE3	UNKNOWN	Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Preterm Neonates
NCT05071638	PHASE3	UNKNOWN	Effect of Autologous Cord Blood Mononuclear Cells for Treatment of Bronchopulmonary Dysplasia in Extremely Preterm Neonates
NCT02097706	PHASE2	RECRUITING	A Novel Drug for Borderline Personality Disorder
NCT03209102	PHASE2	ACTIVE_NOT_RECRUITING	Emotional Regulation and Impulsivity Among Adolescents with Borderline Personality Disorder
NCT04003857	PHASE2	ACTIVE_NOT_RECRUITING	Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial
NCT06446765	PHASE2	RECRUITING	Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
NCT06458933	PHASE2	RECRUITING	Testing Interventions for Borderline Personality Disorder.
NCT06626789	PHASE1/PHASE2	RECRUITING	Brain Signal Training to Enhance Affect Down-regulation
NCT06683014	PHASE2	RECRUITING	MDMA in Borderline Personality Disorder
NCT07099534	PHASE2	NOT_YET_RECRUITING	Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder
NCT07460947	PHASE1/PHASE2	NOT_YET_RECRUITING	A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder
NCT07569198	PHASE2	NOT_YET_RECRUITING	Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
NCT00145678	PHASE2	COMPLETED	Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder
NCT00183651	PHASE2	COMPLETED	Treatment of Suicidal Women With Borderline Personality Disorder
NCT00254748	PHASE2	COMPLETED	Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients
NCT00539188	PHASE2	TERMINATED	N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
NCT00635921	PHASE2	COMPLETED	Ziprasidone in the Treatment of Borderline Personality Disorder
NCT01081314	PHASE1/PHASE2	COMPLETED	Treating PTSD in Patients With Borderline Personality Disorder
NCT01103180	PHASE2	TERMINATED	Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
NCT01133301	PHASE2	COMPLETED	Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder
NCT01189812	PHASE2	COMPLETED	Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
NCT01212588	PHASE2	TERMINATED	Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
NCT02108990	PHASE2	COMPLETED	Acetaminophen and Social Processes
NCT02728778	PHASE2	COMPLETED	Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CITALOPRAM	4	6
FLUOXETINE	4	6
QUETIAPINE	4	4
BREXPIPRAZOLE	4	3
GUANFACINE	4	3
NALTREXONE	4	3
ZIPRASIDONE	4	3
CYCLOSERINE	4	1
DIVALPROEX SODIUM	4	1
DULOXETINE	4	1
ESCITALOPRAM	4	1
FLUDROCORTISONE ACETATE	4	1
HYDROCORTISONE	4	1
KETAMINE	4	1
LAMOTRIGINE	4	1
LITHIUM CARBONATE	4	1
LUMATEPERONE TOSYLATE	4	1
MIDAZOLAM	4	1
MIFEPRISTONE	4	1
NALMEFENE	4	1
RISPERIDONE	4	1
SELEGILINE	4	1
MIDOMAFETAMINE	3	1
PSILOCYBIN	3	1
YOHIMBINE	3	1
FLUDROCORTISONE	2	1
LEVCYCLOSERINE	2	1
MEBUFOTENIN	2	1
VAFIDEMSTAT	2	1
CHEMBL498563	0	2